Microscopic battle scene with antibiotic molecules fighting bacteria, highlighting an unbound colistin molecule.

Colistin Unbound: Why the Future of Antibiotic Treatment Lies in Precision Monitoring

Reese Marlowe monogram
Reese Marlowe in Health & Wellness October 2026 • 4 min read.

"Discover how a novel mass spectrometry method is changing the game in antibiotic therapy, offering hope for patients battling resistant infections."


In the relentless battle against antibiotic-resistant bacteria, colistin stands as a critical last resort. However, this powerful drug walks a narrow therapeutic tightrope: too little, and the infection rages on; too much, and the risk of severe side effects skyrockets. This precarious balance underscores the urgent need for precise therapeutic drug monitoring, but are current methods truly up to the task?

Existing research highlights a significant gap in our understanding: the in vivo unbound fraction of colistin. This is the portion of the drug actively fighting infection, yet it remains poorly understood. The challenge? Developing reliable methods to isolate and quantify this unbound colistin in complex clinical samples.

Now, a groundbreaking study offers a beacon of hope. Researchers have pioneered a novel mass spectrometry method to isolate and quantify unbound colistin, shedding light on its behavior in the body and paving the way for more personalized antibiotic therapies. This article delves into this innovative approach and its potential to transform the future of antibiotic treatment.

AI Search Multiple angles on this topic

Current Use and Detection Challenges

Colistin remains active against many multidrug-resistant Gram-negative pathogens, including Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii, but resistance is increasingly reported worldwide. Recent reviews examine colistin's mechanism of action, toxicities, resistance-detection methods, and intrinsic and acquired resistance mechanisms. With few new antibiotics in development and growing reliance on colistin, understanding resistance and developing innovative solutions has become increasingly urgent.

From Discovery to Last Resort

Colistin, also known as polymyxin E, is a polypeptide antibiotic discovered in the mid-20th century. Initially regarded as a "miraculous molecule" because of its potent bactericidal activity, its use later declined because of safety concerns before returning as a critical last-resort treatment for multidrug-resistant Gram-negative infections. Research into resistance has progressed from earlier methods to the characterization of mobile colistin resistance, or mcr, gene variants, although many resistant strains still have unexplained mechanisms.

The Colistin Conundrum: Why Unbound Monitoring Matters

Microscopic battle scene with antibiotic molecules fighting bacteria, highlighting an unbound colistin molecule.

Colistin's effectiveness is hampered by its unpredictable behavior in the body. Factors like disease state can drastically alter how the drug is distributed, leading to inconsistent plasma levels. Compounding this issue is colistin's narrow therapeutic window, demanding a delicate balance to maximize efficacy and minimize harm. But here's the catch: colistin is administered as an inactive prodrug, colistin methanesulfonate (CMS), which must be converted into its active form to fight infection.

Traditional methods fall short in capturing this complexity. Many rely on measuring total colistin levels, which don't differentiate between the active and inactive forms, or the bound and unbound fractions. This is where monitoring unbound colistin becomes crucial. By focusing on the active portion of the drug, clinicians can gain a clearer picture of its true impact and tailor dosages for optimal results.

Here's why monitoring unbound colistin is a game-changer:
  • Personalized Dosing: Allows clinicians to adjust dosages based on individual patient factors, maximizing efficacy and minimizing toxicity.
  • Improved Outcomes: By ensuring adequate levels of active drug, monitoring can lead to better infection control and reduced rates of resistance.
  • Reduced Side Effects: Precise dosing minimizes the risk of nephrotoxicity and neurotoxicity, common concerns with colistin treatment.
AI Search Multiple angles on this topic

Resistance and Treatment Failure

Colistin resistance is a mounting global health concern, especially among multidrug-resistant and extensively drug-resistant bacterial infections. Resistance can be driven by chromosomal mutations and the spread of plasmid-mediated MCR genes, compromising colistin's efficacy. The cited review reports associations with higher treatment failure rates, prolonged hospitalizations, and increased mortality.

Comparing Treatment Strategies

Recent comparative research has been designed to evaluate colistin monotherapy, colistin-based combination regimens, and alternative antibiotic strategies for multidrug-resistant Gram-negative infections. The stated objective is to assess their comparative efficacy and safety within a unified analytical framework. A separate guide positions colistin as effective against some formidable pathogens while emphasizing concerns about nephrotoxicity and the emergence of resistance.

The study's findings highlight the significant variability in unbound colistin fractions among patients. This underscores the limitations of relying solely on total colistin measurements and emphasizes the need for personalized monitoring strategies to optimize treatment outcomes.

The Road Ahead: Unlocking the Full Potential of Colistin Therapy

This innovative method represents a significant step forward in our ability to understand and optimize colistin therapy. By providing a more accurate picture of the drug's active fraction, it paves the way for personalized dosing strategies that can improve patient outcomes and combat antibiotic resistance. Further research is needed to explore the impact of various factors on unbound colistin levels and to establish clear therapeutic targets for this crucial measurement. The future of antibiotic treatment lies in precision, and this study brings us closer to that reality.

AI Search Multiple angles on this topic

A Continuing Global Health Concern

Colistin resistance represents a mounting global health concern in the context of multidrug-resistant and extensively drug-resistant bacterial infections. Colistin has long served as a critical last-line defence against severe Gram-negative infections, including infections involving Pseudomonas aeruginosa and Acinetobacter species. Its continuing importance underscores the need to address resistance while it remains a key option against difficult-to-treat infections.

Evidence from Clinical Practice

A retrospective study at Ege University Children's Hospital examined real-world colistin therapy in a tertiary-level university hospital. Its findings provide real-world evidence on the role of colistin in treating multidrug-resistant and carbapenem-resistant Gram-negative bacterial infections. The study is particularly relevant to settings with limited access to novel antimicrobials.

What unbound-colistin measurements show in context

  • 34.3%Mean unbound fractions were 34.3% for colistin A and 53.4% for colistin B. In spiked samples, equilibrium dialysis or ultrafiltration produced ranges of 30–42% for A and 43–60% for B; an in-vivo microdialysis study reported 2.8–14.1%.[1]

How clinical safety figures vary across sources

Across five pharmacokinetic studies in critically ill patients, steady-state 24-hour exposure ranged from 11.5 to 566 mg·h/L; healthy adult volunteer studies reported 11.67–51.4 mg·h/L. The broad span in the critically ill group contrasts with the volunteer range, but these figures alone do not explain the difference.[2]

A cited validation work defined a steady-state plasma concentration of 2.42 mg/L as predictive of nephrotoxicity by end of treatment. That concentration threshold concerns total plasma concentration and a safety outcome; it does not itself establish a target for unbound colistin.[3]

What remains unresolved about colistin monitoring

  • What clinical outcome thresholds, if any, can be linked to measured unbound fractions, given the observed individual variation in binding?[3] [4]
  • Can clinical outcomes support susceptibility breakpoints for colistin or polymyxin B across Enterobacterales, Acinetobacter baumannii, and Pseudomonas aeruginosa? The cited rationale says the available data do not permit defining susceptible and resistant categories for these pathogens.[5]
  • How much do differences in patient populations, toxicity definitions, doses, illness severity, and concomitant nephrotoxic medicines contribute to variation in reported kidney-toxicity estimates?[6]
  • How can kidney toxicity be weighed against the treatment role of colistin when nephrotoxicity is described as limiting its effective use for multidrug-resistant Gram-negative infections?[3]

Sources

  1. Investigation of unbound colistin A and B in clinical samples using a mass spectrometry method (dipot.ulb.ac.be)
  2. A Systematic Review of Pharmacokinetic Studies of Colistin and Polymyxin B in Adult Populations (pmc.ncbi.nlm.nih.gov)
  3. Validation of a colistin plasma concentration breakpoint as a predictor of nephrotoxicity in patients treated with colistin methanesulfonate. (pubmed.ncbi.nlm.nih.gov)
  4. Investigation of unbound colistin A and B in clinical samples using a mass spectrometry method. (pubmed.ncbi.nlm.nih.gov)
  5. FDA Rationale for Polymyxin Breakpoints for Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter spp. | FDA (www.fda.gov)
  6. Colistin Nephrotoxicity: Meta-Analysis of Randomized Controlled Trials (pmc.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What is colistin, and why is it so important to monitor it?

Colistin is a powerful antibiotic used as a last resort against resistant bacteria. However, it's a tricky drug because the difference between an effective dose and a toxic dose is small. This means that careful monitoring is essential to ensure it works without causing severe side effects like kidney or nerve damage. Current methods often measure total colistin levels, which can be misleading.

2

What does 'unbound colistin' mean, and why is it so crucial to monitor?

Unbound colistin refers to the portion of the colistin drug that is actively fighting the infection. Colistin is administered as an inactive prodrug, colistin methanesulfonate (CMS), which then converts to its active form. Monitoring unbound colistin is important because it directly indicates how much of the drug is available to target the bacteria. Traditional methods measure total colistin, failing to distinguish between active and inactive forms, leading to inaccurate assessments of efficacy and potential toxicity.

3

Why are the current methods for measuring colistin levels not good enough?

Current methods often fall short because they measure total colistin levels, failing to differentiate between the active and inactive forms of the drug, and also the bound and unbound fractions. This is problematic because only the unbound colistin is actively fighting the infection. Disease states and individual patient factors can drastically alter how colistin behaves, making total colistin measurements unreliable for determining the correct dosage.

4

How does monitoring unbound colistin lead to better patient outcomes?

Monitoring unbound colistin allows for personalized dosing. This means doctors can adjust the colistin dosage based on individual patient factors to maximize the drug's effectiveness while minimizing the risk of side effects, such as kidney or nerve damage. By ensuring adequate levels of active drug, monitoring can lead to better infection control and reduced rates of resistance.

5

How is the new method for monitoring unbound colistin changing antibiotic treatment?

A novel mass spectrometry method has been developed to isolate and quantify unbound colistin. This method allows researchers and clinicians to gain a more accurate understanding of how colistin behaves in the body, which can then be used to optimize treatment strategies. This innovative approach has the potential to transform the future of antibiotic treatment by enabling more personalized and effective therapies.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.